The regional and cellular localization of the two subtypes of dopamine receptors, DI and D2, have been ascertained in rat forebrain by use of fluorescent dopaminergic antagonist ligands. (R,S)-5-(4'-aminophenyl)-8-chloro-2,3,4,5-tetrahydro-3-methyl-[1lH-3-benzazepin-7-ol, the 4'-amino derivative of the high-affinity Dl-specific antagonist SCH 23390, and the D2 selective antagonist N-(p-aminophenethyl)spiperone were chemically derivatized using the fluorescent compound tetramethylrhodamine. Two distinct populations of dopamine receptors exist in the nervous system (1). The D1 dopamine receptor subtype is positively linked to the activation of the cyclic 3',5'-adenosine monophosphate (cyclic AMP) second messenger system, while the D2 dopamine receptor subtype is linked to a variety of signal transduction mechanisms (2, 3). The pharmacological profiles of these two dopaminergic receptor populations can be discriminated on the basis of their agonist/antagonist specificities (4). The regional distributions of these receptor subtypes have been anatomically distinguished through in vitro autoradiographic localization of radiolabeled antagonist ligands. These previous studies indicate that both receptor subtypes are predominantly located in the basal ganglia and mesolimbic systems (5-7). Cellular localization of the striatal D1 dopamine receptor subtype can be approximated when radioligand binding is combined with the localization of the second messenger, cyclic AMP (8, 9) . Previous investigations have shown that the cyclic AMPreactive neurons in the caudate nucleus partially project to the substantia nigra (10), and biochemical investigations substantiate that the striatonigral neurons contain a dopamine-sensitive adenylate cyclase activity (11, 12) consistent with the presence of D1 dopamine receptor binding sites. Although the cellular localization of the striatal D2 receptor is unknown, it has been suggested that the cholinergic interneurons of the caudate nucleus have a D2 binding site (13). The recent report ofthe cDNA sequence for the rat brain D2 receptor may help to resolve this issue (14). Another approach taken by some of us (15) has been the specific derivatization of antagonists for the two dopamine receptor classes by using fluorescent moieties. The advantage of application of these derivatized D1-and D2-selective antagonist probes for anatomical determination of the dopamine receptor subtypes is that cellular localization of the binding sites can be distinguished with much higher resolution than by autoradiographic exposure techniques at these magnifications. We report here the regional and cellular localization of the D1 and D2 receptors in fresh-frozen tissue sections of intact rat forebrain using rhodamine-derivatized (R, S)-5-(4'-aminophenyl)-8-chloro-2,3 ,4,5-tetrahydro-3-methyl-[1Hl-3-benzazepin-7-ol (the 4'-amino derivative of SCH 23390) and N-(p-aminophenethyl)spiperone (NAPS) for the D1 and D2 receptors, respectively.
2,3,4,5-tetrahydro-3-methyl-[1lH-3-benzazepin-7-ol, the 4'-amino derivative of the high-affinity Dl-specific antagonist SCH 23390, and the D2 selective antagonist N-(p-aminophenethyl)spiperone were chemically derivatized using the fluorescent compound tetramethylrhodamine. The modification of these antagonist ligands has allowed the specific, cellular resolution of the DI and D2 receptor binding sites in intact, highly organized regions of forebrain slices in a very rapid experimental time frame. The regional localization of receptors labeled by the fluorescent probes is in agreement with previous receptor autoradiography studies. Moreover, the specific cellular binding patterns for both receptors can now be compared and contrasted to one another in the same tissue by using these fluorescent ligands. D1 receptor sites are most evident within the striatum and exhibit regions of intense "patch" fluorescence corresponding to receptor reactivity in cells and their processes. The distribution of DI receptor binding is highly analogous to the pattern of dopamine terminal histofluorescence in the caudate nucleus. D2 receptor sites are less prevalent overall and may be localized to a subpopulation of the D, fluorescent neurons in the caudate nucleus and nucleus accumbens regions.
Two distinct populations of dopamine receptors exist in the nervous system (1) . The D1 dopamine receptor subtype is positively linked to the activation of the cyclic 3',5'-adenosine monophosphate (cyclic AMP) second messenger system, while the D2 dopamine receptor subtype is linked to a variety of signal transduction mechanisms (2, 3) . The pharmacological profiles of these two dopaminergic receptor populations can be discriminated on the basis of their agonist/antagonist specificities (4) . The regional distributions of these receptor subtypes have been anatomically distinguished through in vitro autoradiographic localization of radiolabeled antagonist ligands. These previous studies indicate that both receptor subtypes are predominantly located in the basal ganglia and mesolimbic systems (5-7). Cellular localization of the striatal D1 dopamine receptor subtype can be approximated when radioligand binding is combined with the localization of the second messenger, cyclic AMP (8, 9) . Previous investigations have shown that the cyclic AMPreactive neurons in the caudate nucleus partially project to the substantia nigra (10) , and biochemical investigations substantiate that the striatonigral neurons contain a dopamine-sensitive adenylate cyclase activity (11, 12) consistent with the presence of D1 dopamine receptor binding sites. Although the cellular localization of the striatal D2 receptor is unknown, it has been suggested that the cholinergic interneurons of the caudate nucleus have a D2 binding site (13) . The recent report ofthe cDNA sequence for the rat brain D2 receptor may help to resolve this issue (14) .
Another approach taken by some of us (15) has been the specific derivatization of antagonists for the two dopamine receptor classes by using fluorescent moieties. The advantage of application of these derivatized D1-and D2-selective antagonist probes for anatomical determination of the dopamine receptor subtypes is that cellular localization of the binding sites can be distinguished with much higher resolution than by autoradiographic exposure techniques at these magnifications. We report here the regional and cellular localization of the D1 and D2 receptors in fresh-frozen tissue sections of intact rat forebrain using rhodamine-derivatized (R, S)-5-(4'-aminophenyl)-8-chloro-2,3 ,4,5-tetrahydro-3-methyl-[1Hl-3-benzazepin-7-ol (the 4'-amino derivative of SCH 23390) and N-(p-aminophenethyl)spiperone (NAPS) for the D1 and D2 receptors, respectively.
METHODS
Male Sprague-Dawley rats (200-250 g) were used to provide experimental tissues. The animals were maintained in a facility accredited by the American Association for Accreditation of Laboratory Animal Care, in strict accordance with the U.S. Public Health Service Guide for the Care and Use ofLaboratory Animals, and all procedures were approved by the University Institutional Animal Care and Use Committee. Rats were sacrificed, and their brains were rapidly removed, blocked in the coronal plane, and frozen at -25°C. Sections were made using a cryostat at 8-to 12-,m thickness rostral to the decussation of the anterior commissure and thaw-mounted onto chrom alum-coated slides. Mounted sections were incubated with one of the rhodamine-labeled dopamine receptor antagonists at 10-1000 nM in phosphatebuffered saline at 4°C overnight in the dark to determine total binding. Fluorescence 
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antagonist at 10 1uM for the definition of nonspecific binding (data not shown). The reactions were terminated by rapid rinses in cold phosphate buffer, four times, 30 sec each, followed by air drying. Just prior to examination, the sections were covered with oil, then viewed using 546/590 nm excitation/emission dichroic filters for the rhodamine fluorophore and the fluorescence optics ofa Zeiss photomicroscope 3. Photomicrographs were made with a 25x immersion lens with a very high numerical aperture, with full-field automatic light metering, and using HP 5 black and white film (Ilford, CIBA-Geigy), pushed 1 to 2 stops and developed using D-19 (Kodak) for high contrast. This procedure normalizes the exposure time and density of the photographic negatives.
Controls for the experiments included the following: (i) examination of the tissues after omission of the fluorescent derivatized receptor antagonist, (ii) use of 100-fold dilutions of the fluorescent probe, (iii) incubation of the fluorescent antagonist probes with the dopaminergic receptor antagonist (+)-butaclamol or its inactive enantiomer (-)-butaclamol at 100 AuM, and (iv) challenge of the binding sites with a 100-fold excess of the respective unlabeled receptor antagonist. In addition, the D1 fluorescent probe was incubated with 50 ,M spiperone, a D2 antagonist, to determine competitive crossreactive receptor binding interactions in the tissue sections, and an analogous experiment was performed using the D2 fluorescent probe and the D1 selective antagonist SCH 23390.
Radioligand binding assays using freshly prepared rat striatal membranes were performed exactly as previously described (15) .
RESULTS
The molecular characterization and homologous receptor affinities of the rhodamine-derivatized antagonists have been reported (15) . Table 1 shows the homologous and heterologous affinity constants for each fluorescent ligand. When compared with the opposite receptor subtype, the D1 fluorescent probe is about 70,000-fold selective for D1 receptors while the D2 probe is 300-fold selective for D2 receptors. Moreover, the cross reactivities for the different receptor subtype affinities are such that significant labeling of the opposite subtype would not occur at the 100 nM concentrations of fluorescent probe used.
The SCH 23390-rhodamine and NAPS-rhodamine fluorescent probes demonstrated faithful morphological reproduction of the dopamine receptor subtype distributions previously reported using in vitro autoradiographic methods. A diagrammatic representation of the forebrain regions showing the most intense fluorescence is presented in Fig. 1 . The highest intensity of receptor sites for both D1 and D2 dopamine receptor subtypes is in the caudate nucleus proper. Fluorescent labeling could also be distinguished in the frontal cortex, somatosensory motor cortex, the piriform cortex, and in the nucleus accumbens of the mesolimbic system. The fluorescence exhibited following application of the D1 recep- tor ligand far exceeded that visualized for the D2 population, except in regions of the frontal cortex.
The anatomical distribution of the D1 fluorescent ligand in the three forebrain regions is shown in Fig. 2 , including cellular localization of total receptor binding sites in the caudate nucleus (A), nucleus accumbens (B), and somatosensory motor cortex (C). The caudate nucleus demonstrates an uneven fluorescence distribution throughout the neuropil, in contrast to other forebrain areas exhibiting D1 receptor binding. Addition of (-)-butaclamol did not change the cellular disposition of the receptor binding in the striatum (D) nor did the inclusion of the selective D2 receptor antagonist spiperone (G). However, the fluorescent probe was significantly displaced from D1 binding sites when the dopaminergic antagonist (+)-butaclamol (E) or the D1-selective antagonist SCH 23390 (F) were included in the incubation with the rhodamine-labeled D1 antagonist probe. Various regions of the forebrain are not reactive for the D1 fluorescence, as seen in the vicinity of the endopyriform nucleus (H), which does not contain dopamine receptors, following incubation with the rhodamine-derivatized SCH 23390 ligand.
D2 receptor fluorescence is shown in Fig. 3 for the same areas of the forebrain, including the caudate nucleus (A), nucleus accumbens (B), and somatosensory motor cortex (C). The cellular fluorescence for this dopamine receptor subtype is qualitatively similar to that of D1 binding (Fig. 2) , but the intensity of fluorescence is diminished. This dopamine receptor subtype shows a close association with cell bodies of large diameter in the caudate nucleus and of medium size in other regions. The assessment of fluorescent probe specificity in the tissue sections is apparent when the optically paired antagonist compounds (+)-and (-)-butaclamol are added to the incubation. The optically inactive (-) enantiomer does not alter the pattern of D2 binding medium-sized neurons of the nucleus accumbens (H) can be seen at high magnification. The pattern of cellular localization is confined to the peripheral rim of cytoplasm, suggesting binding to the plasma membrane, and is granular in appearance. In this fortuitous section an extensive process can be seen radiating away from the soma (arrowheads). DISCUSSION The regional and cellular patterns ofdistribution ofthe D1 and D2 populations of dopamine receptors have been demonstrated in fresh-frozen rat forebrain sections through the use of rhodamine-derivatized, subtype-specific antagonists. Bio (Table 1 ). The selectivity of the derivatized ligands was further substantiated by their morphological distribution within the telencephalon (Fig. 1) . Regional distribution of the D1 receptor was particularly (H) Total binding in the nucleus accumbens. The most intense binding occurs at the peripheral cytoplasm, and it is not homogeneous in fluorescence. The arrowheads denote a process emanating from the somata of one of the D2 expressing neurons. concentrated in the basal ganglia, as previously determined using in vitro autoradiography of [3H]SCH 23390 (6-9), 125I-labeled SCH 23982 (5, 8, 9) , [3H]SKF 38393 (17, 18) , and [3H]dopamine (17) . Regional localization ofthe D2 receptor in the frontal cortex, caudate-putamen, and mesolimbic system also mirrored previous reports of its distribution based on autoradiographic receptor binding methods (6, 13) . Additionally, specificity of the derivatized antagonist ligands in the tissue sections was determined by (i) using the optically paired enantiomers of butaclamol, (ii) challenge with unlabeled antagonist ligand, and (iii) incubation with the contrasting, unlabeled receptor antagonist ligand for both receptor subtypes. The optically active (+)-butaclamol blocked the fluorescence visualized in total D1 and D2 binding experiments when added to the incubation solution, while (-)-butaclamol did not diminish the fluorescent staining patterns. Moreover, challenge of the D1 subtype with unlabeled SCH 23390 abolished the fluorescence in forebrain regions, while inclusion of the contrasting antagonist, spiperone, had no effect. An analogous demonstration of fluorescence specificity and selectivity was determined for the D2 fluorescent antagonist probe, rhodamine-NAPS, in which staining patterns in the forebrain were blocked by inclusion of unlabeled spiperone in the incubation, while SCH 23390 had no effect.
The advantage of using fluorescently derivatized ligands to localize dopamine receptors is the cellular resolution made possible. The chemical modification of the probes was accomplished by using a known quantity of rhodamine molecule per receptor antagonist, thereby enabling a much more precise point-to-point relationship to be derived between the intensely fluorescent elements in the tissue and the dopamine receptor subtype. This finding is readily apparent for the localization of D2 receptor sites in the caudate nucleus and the nucleus accumbens (Fig. 3 A, B , and H) in which specific characterization of the neuronal type can be accomplished. Direct labeling of the antagonists does decrease the amplification of the specific cellular signal over the general background noise ratio in the regions of elevated receptor concentration, making precise quantitation of the data exceedingly difficult with the fluorescent labels. For example, cellular D1 receptor distribution in the caudate nucleus circumscribed to individual neurons is difficult to resolve because of the dense concentration of receptor binding sites in this structure (Fig. 2 A, D, and G) . The additional necessity of visualization of fluorescence using a high-resolution immersion lens with a large numerical aperture further confounds this approach, as regional fluorescence is difficult to capture at low magnification. However an important finding of the present work is the demonstration of receptor binding sites in a pattern that is very similar to dopamine terminal histofluorescence in this structure. Moreover, an uneven distribution for the D1 receptor can be distinguished within the caudate nucleus, reminiscent of the patch compartment of the striatal mosiac (19) . It has been reported that the medium spiny neurons of the striatal patch compartment in the rat project to the substantia nigra, pars compacta (20, 21) , an area that demonstrates a pronounced dopamine-sensitive adenylate cyclase activity (12) . Using radioligand binding morphochemistry, we have previously confirmed the presence of D1 binding sites on cyclic AMP-immunoreactive medium-sized striatal neurons (8) (9) (10) . The present data extend these findings in that the fluorescent cellular elements have the cytoarchitectural characteristics of the striatonigral population of the caudate nucleus (22) and are macroscopically organized into a patchy mosaic.
The most significant finding of the present investigation is the demonstration of an anatomical substrate containing the D2 dopamine receptor. These reactive cells are distinctively neuronal in their morphology, having a thin rim of cytoplasm and a soma diameter of =15 ,m, characteristics of the medium spiny neuron in the striatum (22) . The largediameter, cholinergic interneuron population in the striatum has also been purported to express D2 receptor binding sites (13) , and rhodamine-NAPS was found to be associated with the occasional large neuron in the striatum (Fig. 3A) . As expected from the results of radioligand binding studies, the prevalence of D2 receptor fluorescence was less than that of D1 and probably consists of a subset of D1 receptor expressing neurons, especially in the caudate nucleus. Final confirmation of this point awaits the application of dopaminergic antagonist probes derivatized with contrasting fluorophores (15) to the frozen tissue sections.
The maintenance of very high affinity for the dopamine receptors following chemical modification of their antagonists by rhodamine, combined with the replication of receptor distributions using alternative methodologies, substantiates that these fluorescent probes detect the appropriate receptor subtypes in the brain slices. It is anticipated that the simultaneous cellular localization of the two dopamine receptor populations will be possible by the use of fluorescently labeled probes that have been derivatized with fluorophores that can be excited and emit at different wavelengths. Such probes should prove most useful in future investigations for the analysis of cellular dopamine receptor distributions in pharmacologically and experimentally manipulated animals.
